Drug
Semaxinib clinical trials
Also written semaxanib, SU5416 and Sugen 5416.
- studies test it
- 22
- open now
- 0
- in phase 3
- 0
- first study started
- 1998
How studies write it
Studies that test it under each name
Studies by the year they started
19 studies that test it; most in 2000 (16)
| Year | Studies |
|---|---|
| 1998 | 1 |
| 2000 | 16 |
| 2001 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 11
- Phase 2
- 14
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 19
National Cancer Institute (NCI) (8) · Case Comprehensive Cancer Center (3) · SUGEN (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1) · AIDS Malignancy Consortium (1) · University of Chicago (1) · Fox Chase Cancer Center (1) · Gynecologic Oncology Group (1)
Often tested with
Tested in the same studies.
Irinotecan (1) · Liposomal Daunorubicin Citrate (1) · Daunorubicin citrate (1) · Daunorubicin (1) · Doxorubicin (1) · Paclitaxel (1) · Carboplatin (1)
Studies
Open first, then newest update. How each study uses Semaxinib is read from its arms, and is right about nine times in ten.
Testing it · 22
- SU5416 in Treating Patients With Recurrent Astrocytoma or Mixed Glioma That Has Not Responded to Radiation TherapyCompletedPhase 1/2Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT00004868Written as semaxanib
- SU5416 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedPhase 2AIDS Malignancy ConsortiumNCT00005042Written as semaxanib
- SU5416 Plus Hormone Therapy and Radiation Therapy in Treating Patients With Prostate CancerCompletedPhase 1University of ChicagoNCT00026377Written as SU5416
- SU5416 in Treating Patients With Refractory or Relapsed Multiple MyelomaCompletedPhase 2Fox Chase Cancer CenterNCT00006013Written as semaxanib
- SU5416 in Treating Patients With Persistent or Recurrent Cervical CancerCompletedPhase 2Gynecologic Oncology GroupNCT00026260Written as semaxanib
- Radiation Therapy With or Without SU5416 in Treating Patients With Soft Tissue SarcomaCompletedPhase 1/2Radiation Therapy Oncology GroupNCT00023725Written as semaxanib
- SU5416 in Treating Patients With Malignant MesotheliomaCompletedPhase 2National Cancer Institute (NCI)NCT00006014Written as semaxanib
- SU5416 in Treating Patients With Metastatic or Locally Recurrent Colorectal CancerTerminatedPhase 2National Cancer Institute (NCI)NCT00006001Written as semaxanib
- SU5416 in Treating Patients With Advanced, Metastatic, or Recurrent Soft Tissue SarcomasCompletedPhase 2National Cancer Institute (NCI)NCT00005862Written as semaxanib
- SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously TreatedTerminatedPhase 2National Cancer Institute (NCI)NCT00006003Written as semaxanib
- SU5416 and Irinotecan in Treating Patients With Advanced Colorectal CancerCompletedPhase 1/2National Cancer Institute (NCI)NCT00005818Written as semaxanib
- Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial TherapyCompletedPhase 1/2National Cancer Institute (NCI)NCT00005942Written as semaxanib
- SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous TreatmentTerminatedPhase 2National Cancer Institute (NCI)NCT00009919Written as semaxanib
- SU5416 in Treating Patients With AIDS-Related Kaposi's SarcomaCompletedPhase 1PfizerNCT00003720Written as semaxanib
- SU5416 and Doxorubicin in Treating Patients With Stage IIIB or Stage IV Inflammatory Breast CancerCompletedPhase 1Case Comprehensive Cancer CenterNCT00005822Written as semaxanib
- SU5416 in Treating Patients With Advanced Solid TumorsCompletedPhase 1Case Comprehensive Cancer CenterNCT00005642Written as semaxanib
- SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and NeckCompletedPhase 1Case Comprehensive Cancer CenterNCT00005647Written as semaxanib
- SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and NeckCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00006361Written as semaxanib
- SU5416 in Treating Children With Recurrent or Progressive Brain TumorsTerminatedPhase 1Pediatric Brain Tumor ConsortiumNCT00006247Written as semaxanib
- SU5416 and Carboplatin to Treat Ovarian CancerCompletedPhase 1National Cancer Institute (NCI)NCT00006155Written as SU5416 and carboplatin
See all 22 studies that test Semaxinib →
Given in every arm · 2 — Semaxinib is usual care beside what is tested
- SU5416 Compared to Dexamethasone in Treating Patients With Progressive Prostate Cancer That Has Not Responded to Hormone TherapyCompletedPhase 2University of ChicagoNCT00006002Written as semaxanib
- Thalidomide and SU5416 in Treating Patients With Metastatic MelanomaCompletedPhase 2National Cancer Institute (NCI)NCT00017316Written as semaxanib
Codes
What other systems call Semaxinib · ClinicalTrials.gg INT004121
- MeSH (NLM) C116890SemaxinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 71IA9S35AJSEMAXANIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C116890 | Semaxinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 71IA9S35AJ | SEMAXANIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.